BioAscent Discovery

Founded in 2013, BioAscent is a Scotland-based contract research organization (CRO) specializing in integrated small molecule drug discovery services. The company provides a comprehensive suite of capabilities, including medicinal and synthetic chemistry, in silico discovery, biochemical and cellular assay development, and DMPK. Operating from a dedicated R&D facility in Newhouse, UK, BioAscent utilizes advanced laboratory infrastructure and in-house diversity and fragment libraries to advance projects from target concept through to preclinical candidate selection. Its drug discovery teams are supported by an automated compound management and logistics platform, which allows for the secure, scalable storage and distribution of chemical libraries for global clients. By integrating these scientific and logistical disciplines at a single site, the company offers a cohesive, science-led approach designed to accelerate drug development pipelines across diverse therapeutic indications.

BioAscent’s services are highly valued by biotechnology and pharmaceutical partners worldwide, ranging from large academic institutions to innovative biotech firms. The company supports partners by solving complex challenges in hit-to-lead and lead optimization, backed by a team with extensive industry experience and modern instrumentation. Proof of its scientific impact is demonstrated through its successful collaborations, such as its work with the German Cancer Research Center (DKFZ) on developing selective enzyme inhibitors. Beyond its scientific project work, BioAscent serves as a critical partner for compound logistics, currently supporting numerous international organizations with the aggregation, quality control, and global shipping of their compound collections. This integrated model ensures that customers have access to both technical expertise and essential infrastructure required to move drug discovery programs efficiently toward clinical milestones.